What is it about?

Overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam

Featured Image

Why is it important?

Provides a pragmatic overview on the new BL/BLIs and cefiderocol

Perspectives

New antibiotics against resistant Gram-negative bacteria arrive quickly, and keeping up with their spectrum, pharmacology and clinical data is hard even for specialists. Together with microbiologists, pharmacologists and clinicians from several Italian centres, we wanted to build a single, practical guide that can be consulted at the bedside.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: Microbiological, Clinical, and PK/PD Features of the New  Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase  Inhibitors in Combination and Cefiderocol—An All-Inclusive  Guide for Clinicians, December 2023, Authorea, Inc.,
DOI: 10.22541/au.170259036.66886277/v1.
You can read the full text:

Read

Contributors

The following have contributed to this page